#AveXis Inc (AVXS) - Prohost Biotech

Regenxbio: Promising Results from RGX-121 Gene Therapy for Mucopolysaccharidosis Type II (MPS II)

Regenxbio Results from RGX-121 for MPSII Regenxbio ( RGNX ) announced interim data from Phase I/II trial of RGX-121 for Mucopolysaccharidosis Type II ( MPS II) . RGX-121 is designed to deliver the ge...

P

Prohost Biotech

Dec 19, 2019

1m

0

News & Comments

When Negative Reactions to Biotechnology News Mislead. The Case of Regenxbio.

Regenxbio Misleading Selloff A selloff of Regenxbio (RGNX) stock, following the FDA’s partial hold on the intrathecal administration of AVXS-101, is unwarranted and totally misleading. Why? Becaus...

P

Prohost Biotech

Oct 31, 2019

The Value of the Biotech Companies Continued

Prohost Letter #435 The Value of the Biotech Companies A Continuation of Prohost Letter #434 A Recap The biotech near and long-term values, we insist, must be based on the firms’ scientific capabiliti...

P

Prohost Biotech

Sep 23, 2019

About RegenxBio's Agreement with Clearside Biomedical and More

Diseases of the Back of the Eye Diseases of the back of the eye, such as: age-related wet macular degeneration, diabetic retinopathy and diabetic macular edema, are currently managed with injections o...

P

Prohost Biotech

Sep 10, 2019

The Value of the Biotech Companies

Prohost Letter #434 Special Issue The Value of the Biotech Companies With a strong economy and an unemployment rate reaching the lowest percentage in decades we are witnessing strange, if not bizarre,...

P

Prohost Biotech

Aug 12, 2019

Novartis: More promising data from a Phase 3 trial with AveXis' gene therapy Zolgensma® for Spinal Muscular Atrophy Type 1

Novartis Has More Promising Data from Their Phase 3 Gene Therapy Trial with AveXis AveXis Inc., a Novartis ( NVS ) company, announced positive interim data from its Phase 3 STR1VE trial of Zolgensma ®...

P

Prohost Biotech

Apr 17, 2019

1m

0

News & Comments

Successful results were announced by uniQure for its gene therapy, AMT-061, on hemophilia B patients

The United States FDA granted Breakthrough Therapy Designation to AMT-061. The European Medicines Agency gave it access to the Priority Medicine (PRIME) regulatory initiative. Gene therapy firm, uniQ...

P

Prohost Biotech

Feb 11, 2019

Now You See It, Now You Don't

Now You See it, Now You Don’t Deliberate Omissions of Real Facts Real facts might be displayed or concealed depending on the news announcers’ or bloggers’ self-interests. The following contains cases...

P

Prohost Biotech

Jan 28, 2019

When common sense fails to explain market performance

Prohost Letter #425 When Common Sense Fails to Explain the Market Performance It is not unusual for the stock market to be in a selloff mood for a few days . However, in the last couple of months, the...

P

Prohost Biotech

Dec 3, 2018

Following the Stars. Less Science and More Logic

Prohost Letter #424 Following the Stars Less Science and More Logic We reiterate that while a human star is born every once in a while on Earth, several stars born daily in research labs may be design...

P

Prohost Biotech

Oct 14, 2018

1m

5

News & Comments

Novartis Pleased the Market with Its Q2 Financial Results and Pleased Us with Its Great Scientific Achievements. See Also: The Role AveXis and RegenxBio are Playing Towards the Future Success of Novartis

Novartis’ (NVS) financials results exceeded analysts’ expectations. The firm’s research institutions’ strategy, well-designed structure, plans for innovation and accurate execution led to a wealthy an...

P

Prohost Biotech

Jul 19, 2018

New stock selection and re-evaluation

Prohost Letter #422 SUMMARY OF THE PAST ISSUE ARTICLE - REVISITING PROMISING FIRMS (PART1) - The firms we tackled in the past issue comprised: 1. Firms we liked and added to our portfolio. 2. Firms we...

P

Prohost Biotech

Jun 8, 2018

Revisiting Biotech Companies We Highlighted

Prohost Letter #421 PRIVATE LESSONS - Stock prices of publicly-traded biotech companies oscillate for the same reasons other industries’ stock prices swing all day long. The fluctuations are the out...

P

Prohost Biotech

May 25, 2018

AveXis Drug’s Data for Spinal Muscular Atrophy Highlights Gene Therapy

The Week in Review #21 Part 2 THE MARKET (2) - Our remarks in the past Week in Review included our confidence that the attempts by negative investors to drive the market crazy will not deprive the ma...

P

Prohost Biotech

Apr 30, 2018

Novartis to acquire AveXis. Would the Approval of AVXS-101, If Any, Impact the Sales of Ionis’ Spinraza?

NOVARTIS TO ACQUIRE AVEXIS A few months ago, Novartis (NVS) CEO agreed to cash out of the company’s consumer health joint venture with GlaxoSmithKline (GSK) , which brought in cash intended to fur...

P

Prohost Biotech

Apr 10, 2018

The Year in Review Part 2

Prohost Letter #416 Part 2 2017 - A YEAR OF BREAKTHROUGH TECHNOLOGIES, BREAKTHROUGH PRODUCTS, IMPROVEMENTS ON PROMISING BREAKTHROUGH TREATMENTS, DECIPHERING IMPORTANT LIFE SCIENCE MYSTERIES, PINPOINTI...

P

Prohost Biotech

Jan 10, 2018

The Year in Review Part 1

Prohost Letter #416 Part 1 The Year In Review - 2017 Unheard of Programs - AN AWESOME YEAR for the biotech sector regarding its accomplishments. Many of the accomplished programs were unheard of regar...

P

Prohost Biotech

Dec 31, 2017

Prohost Letter #415

Prohost Letter #415 New Promising Technologies PROTAC - A Technology That Offers a Superior Class of Drugs PROTAC is an approach that created a new class of drugs described as superior and far less to...

P

Prohost Biotech

Dec 3, 2017

1m

2